Caliway Biopharmaceuticals C, TW0006919004

Canada authorized Caliway phase 3 amendment: what it means for Caliway Biopharmaceuticals C stock

Published on 10/08/2026 at 12:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Canada approved a phase 3 amendment on September 21, 2026. On October 8, 2026, Caliway Biopharmaceuticals C stock had TWD 120.6 billion market value.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals C (ISIN TW0006919004) was linked to a Canadian authorization for a phase 3 amendment to its CBL-514 study on September 21, 2026. MarketScreener reported the authorization, giving the company's lead clinical program another phase 3 development milestone.

CBL-514 moves toward a larger test

The amendment concerned CBL-514, Caliway's investigational treatment for fat reduction and Dercum's disease. The company is also developing CBA-539 in preclinical programs targeting central obesity, hyperpigmentation and skin aging.

The clinical milestone matters because phase 3 programs require larger and more demanding evidence than earlier-stage studies. Caliway's pipeline therefore remains tied to execution risk, regulatory review and the conversion of clinical findings into later commercial opportunities.

Second-quarter numbers show a development-stage profile

In the second quarter of 2026, revenue was TWD 3.57 million and net loss was TWD 222.52 million. The loss was 62.77 percent larger than the TWD 136.48 million loss recorded in the first quarter of 2026, based on standardized financial data for 6919.TW.

The balance sheet showed TWD 9.43 billion in total assets on June 30, 2026, including TWD 4.05 billion in cash and short-term investments. That capital base gives the company resources for research programs, while the quarterly loss underlines the cost of advancing clinical candidates.

Stock valuation stays wide across the year

Caliway's Taiwan-listed stock was TWD 77.50 on October 8, 2026, down 0.77 percent from the prior close of TWD 78.10. Its 52-week range was TWD 75.10 to TWD 188.00, placing the latest price TWD 2.40 above the low and TWD 110.50 below the high.

Market capitalization was TWD 120.6 billion on October 8, 2026. The combination of a broad annual range, ongoing clinical spending and a phase 3 development milestone leaves trial progress as the key measurable operating factor.

Clinical progress sets the next marker

The September 21 authorization is older than the latest phase 2 data reported in the market, but it remains a separate regulatory milestone for CBL-514. The second-quarter results and June 30 balance-sheet figures provide the financial context for a biotechnology company funding clinical development before product revenue can become material.

On October 8, 2026, Caliway Biopharmaceuticals traded at TWD 77.50 on the Taiwan Stock Exchange, with the session change at minus 0.77 percent versus TWD 78.10.